Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRC-002 SAD, MAD, and Food Effect Study in Healthy Participants
NCT07699120Phase 1Enrolling by invitation
- Sponsor
- Biopharmaceutical Research Company
- Start
- Jun 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BRC-002 (3 arms), sponsored by Biopharmaceutical Research Company. Primary endpoint: Safety and tolerability of BRC-002 up to 144 hours. Started Jun 2026; status: enrolling by invitation.
02
Drugs
BRC-002
Beyond the preview
Go deeper on NCT07699120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699120.